Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 48

1.

Failure of rituximab is associated with a poor outcome in diffuse large B cell lymphoma-type post-transplant lymphoproliferative disorder.

Jain MD, Lam R, Liu Z, Stubbins RJ, Kahlon A, Kansara R, Goswami R, Humar A, Prica A, Sehn LH, Slack GW, Crump M, Savage KJ, Peters AC, Kuruvilla J.

Br J Haematol. 2020 Feb 18. doi: 10.1111/bjh.16304. [Epub ahead of print]

PMID:
32068243
2.

Cost-effectiveness of first-line treatment options for patients with advanced-stage Hodgkin lymphoma: a modelling study.

Vijenthira A, Chan K, Cheung MC, Prica A.

Lancet Haematol. 2020 Feb;7(2):e146-e156. doi: 10.1016/S2352-3026(19)30218-2. Epub 2020 Jan 13.

PMID:
31948928
3.

Impact of 18F-fluorodeoxyglucose PET/CT in the management of patients with plasma cell disorders.

Shachar B, Prica A, Anconina R, Hawsawy A, MacCrostie P, Langer D, Metser U.

Nucl Med Commun. 2020 Jan;41(1):34-39. doi: 10.1097/MNM.0000000000001113.

PMID:
31764598
4.

Evaluation of Lymphadenopathy and Suspected Lymphoma in a Lymphoma Rapid Diagnosis Clinic.

Nixon S, Bezverbnaya K, Maganti M, Gullane P, Reedijk M, Kuruvilla J, Prica A, Kridel R, Kukreti V, Bennett S, Rogalla P, Delabie J, Pintilie M, Crump M.

JCO Oncol Pract. 2020 Jan;16(1):e29-e36. doi: 10.1200/JOP.19.00202. Epub 2019 Oct 1.

PMID:
31573831
5.

Toxicity and survival outcomes of autologous stem cell transplant in multiple myeloma patients with renal insufficiency: an institutional comparison between two eras.

Li AY, Atenafu EG, Bernard RS, Masih-Khan E, Reece D, Franke N, Tiedemann R, Prica A, Trudel S, Kukreti V, Chen CI.

Bone Marrow Transplant. 2019 Sep 26. doi: 10.1038/s41409-019-0697-8. [Epub ahead of print]

PMID:
31558786
6.

Emerging therapies for the treatment of relapsed or refractory diffuse large B cell lymphoma.

Skrabek P, Assouline S, Christofides A, MacDonald D, Prica A, Sangha R, Matthews BA, Sehn LH.

Curr Oncol. 2019 Aug;26(4):253-265. doi: 10.3747/co.26.5421. Epub 2019 Aug 1. Review.

7.

Clinical and Cost-effectiveness of a Comprehensive geriatric assessment and management for Canadian elders with Cancer-the 5C study: a study protocol for a randomised controlled phase III trial.

Puts MTE, Hsu T, Mariano C, Monette J, Brennenstuhl S, Pitters E, Ray J, Wan-Chow-Wah D, Kozlowski N, Krzyzanowska M, Amir E, Elser C, Jang R, Prica A, Krahn M, Beland F, Bergman S, Koneru R, Lemonde M, Szumacher E, Zidulka J, Fung S, Li A, Emmenegger U, Mehta R, Flemming K, Breunis H, Alibhai SMH.

BMJ Open. 2019 May 10;9(5):e024485. doi: 10.1136/bmjopen-2018-024485.

8.

Outcomes of patients with relapsed low-grade lymphoma retreated with rituximab are similar to rituximab naïve patients.

Vijenthira A, Maganti M, Kukreti V, Kuruvilla J, Tiedemann R, Chen C, Crump M, Prica A.

Leuk Lymphoma. 2019 Oct;60(10):2576-2579. doi: 10.1080/10428194.2019.1585837. Epub 2019 Apr 18. No abstract available.

PMID:
30997853
9.

Treatment of Multiple Myeloma: ASCO and CCO Joint Clinical Practice Guideline.

Mikhael J, Ismaila N, Cheung MC, Costello C, Dhodapkar MV, Kumar S, Lacy M, Lipe B, Little RF, Nikonova A, Omel J, Peswani N, Prica A, Raje N, Seth R, Vesole DH, Walker I, Whitley A, Wildes TM, Wong SW, Martin T.

J Clin Oncol. 2019 May 10;37(14):1228-1263. doi: 10.1200/JCO.18.02096. Epub 2019 Apr 1.

PMID:
30932732
10.

Improving CD20 antibody therapy: obinutuzumab in lymphoproliferative disorders.

Prica A, Crump M.

Leuk Lymphoma. 2019 Mar;60(3):573-582. doi: 10.1080/10428194.2018.1498490. Epub 2019 Jan 22.

PMID:
30668192
11.

Effect of PET/CT on the Management and Outcomes of Participants with Hodgkin and Aggressive Non-Hodgkin Lymphoma: A Multicenter Registry.

Metser U, Prica A, Hodgson DC, Mozuraitis M, Eberg M, Mak V, Green B, Singnurkar A, Dudebout J, MacCrostie P, Tau N, Mittmann N, Langer DL.

Radiology. 2019 Feb;290(2):488-495. doi: 10.1148/radiol.2018181519. Epub 2018 Dec 4.

PMID:
30511907
12.

Significance of treatment response when managing patients with primary central nervous system lymphoma.

Chan H, Moraes FY, Berlin A, Crump M, Mason W, Laperriere N, Kuruvilla J, Prica A.

Leuk Lymphoma. 2019 Feb;60(2):349-357. doi: 10.1080/10428194.2018.1474524. Epub 2018 Jul 3.

PMID:
29966463
13.

Single-center Experience in Treating Patients With t(4;14) Multiple Myeloma With and Without Planned Frontline Autologous Stem Cell Transplantation.

Chan H, Phillips M, Maganti M, Farooki S, Piza Rodriguez G, Masih-Khan E, Chen C, Prica A, Reece D, Tiedemann R, Trudel S, Kukreti V.

Clin Lymphoma Myeloma Leuk. 2018 Mar;18(3):225-234. doi: 10.1016/j.clml.2017.12.009. Epub 2018 Jan 5.

PMID:
29397346
14.

Fertility preservation in post-pubescent female cancer patients: A practical guideline for clinicians.

Srikanthan A, Amir E, Bedard P, Giuliani M, Hodgson D, Laframboise S, Prica A, Yee K, Greenblatt E, Lewin J, Gupta A.

Mol Clin Oncol. 2018 Jan;8(1):153-158. doi: 10.3892/mco.2017.1486. Epub 2017 Nov 3.

15.

Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin's lymphoma: an international, multicentre, single-arm, phase 1-2 trial.

O'Connor OA, Lue JK, Sawas A, Amengual JE, Deng C, Kalac M, Falchi L, Marchi E, Turenne I, Lichtenstein R, Rojas C, Francescone M, Schwartz L, Cheng B, Savage KJ, Villa D, Crump M, Prica A, Kukreti V, Cremers S, Connors JM, Kuruvilla J.

Lancet Oncol. 2018 Feb;19(2):257-266. doi: 10.1016/S1470-2045(17)30912-9. Epub 2017 Dec 21. Erratum in: Lancet Oncol. 2018 Mar;19(3):e137.

PMID:
29276022
16.

Connecting the Dots.

Rush RP, Saltman AP, Prica AA, Breiner A, Detsky AS.

N Engl J Med. 2017 Sep 7;377(10):978-984. doi: 10.1056/NEJMcps1613804. No abstract available. Erratum in: N Engl J Med 2018 May 10;378(19):1854. N Engl J Med. 2018 Apr 20;378(19):1854.

PMID:
28877025
17.

Recurrent Body Rash Warranted Second Desensitization With Acyclovir in a Myeloma Patient: A Case Report.

Seki JT, Ng P, Lam W, Cote J, Prica A.

J Clin Med Res. 2017 Aug;9(8):725-728. doi: 10.14740/jocmr2772w. Epub 2017 Jul 1.

18.

Financial Impact of Cancer Drug Wastage and Potential Cost Savings From Mitigation Strategies.

Leung CYW, Cheung MC, Charbonneau LF, Prica A, Ng P, Chan KKW.

J Oncol Pract. 2017 Jul;13(7):e646-e652. doi: 10.1200/JOP.2017.022905. Epub 2017 Jun 12.

PMID:
28605255
19.

Emerging therapies for the treatment of relapsed or refractory follicular lymphoma.

MacDonald D, Prica A, Assouline S, Christofides A, Lawrence T, Sehn LH.

Curr Oncol. 2016 Dec;23(6):407-417. doi: 10.3747/co.23.3405. Epub 2016 Dec 21. Review.

20.

Rituximab in Lymphoma and Chronic Lymphocytic Leukaemia: A Practice Guideline.

Prica A, Baldassarre F, Hicks LK, Imrie K, Kouroukis T, Cheung M; Members of the Hematology Disease Site Group of the Cancer Care Ontario Program in Evidence-based Care.

Clin Oncol (R Coll Radiol). 2017 Jan;29(1):e13-e28. doi: 10.1016/j.clon.2016.09.004. Epub 2016 Oct 14.

PMID:
27746042
21.

Cyclophosphamide and Bortezomib With Prednisone or Dexamethasone for the Treatment of Relapsed and Refractory Multiple Myeloma.

Reece DE, Trieu Y, Masih-Khan E, Atenafu EG, Chen C, Prica A, Tiedemann R, Trudel S, Kukreti V.

Clin Lymphoma Myeloma Leuk. 2016 Jul;16(7):387-94. doi: 10.1016/j.clml.2016.04.012. Epub 2016 May 10.

PMID:
27349765
22.

Granulocyte colony-stimulating factor in secondary prophylaxis for advanced-stage Hodgkin lymphoma treated with ABVD chemotherapy: a cost-effectiveness analysis.

Cheung MC, Prica A, Graczyk J, Buckstein R, Chan KK.

Leuk Lymphoma. 2016 Aug;57(8):1865-75. doi: 10.3109/10428194.2015.1117609. Epub 2016 Jan 12.

PMID:
26758765
23.

Clinical Reasoning: A 66-year-old man with recurrent multi-territory infarcts.

Kouzmitcheva E, Steriade C, Prica A, Hazrati LN, Mandell DM.

Neurology. 2015 Jun 9;84(23):e195-201. doi: 10.1212/WNL.0000000000001662. No abstract available.

PMID:
26054898
24.

Monthly blood transfusions decrease after four months of azacitidine.

Tseng E, Prica A, Zhang L, Mittmann N, Seung SJ, Callum J, Kim T, Wells RA, Buckstein R.

Vox Sang. 2015 Aug;109(2):163-7. doi: 10.1111/vox.12266. Epub 2015 Apr 20.

PMID:
25899763
25.
26.

Pyoderma gangrenosum secondary to azacitidine in myelodysplastic syndrome.

Tseng E, Alhusayen R, Sade S, Buckstein R, Prica A.

Br J Haematol. 2015 May;169(4):461. doi: 10.1111/bjh.13341. Epub 2015 Mar 12. No abstract available.

PMID:
25765235
27.

Safety and efficacy of thrombopoietin-receptor agonists in myelodysplastic syndromes: a systematic review and meta-analysis of randomized controlled trials.

Prica A, Sholzberg M, Buckstein R.

Br J Haematol. 2014 Dec;167(5):626-38. doi: 10.1111/bjh.13088. Epub 2014 Aug 26. Review.

PMID:
25155450
28.

Combined modality therapy versus chemotherapy alone as an induction regimen for primary central nervous system lymphoma: a cost-effectiveness analysis.

Prica A, Chan K, Cheung M.

Neuro Oncol. 2014 Oct;16(10):1384-91. doi: 10.1093/neuonc/nou057. Epub 2014 May 5.

29.

Myelodysplastic syndrome successfully treated with adalimumab.

Prica A, Buckstein R.

J Clin Oncol. 2015 Jan 10;33(2):e4-6. doi: 10.1200/JCO.2013.49.4948. Epub 2014 Feb 24. No abstract available.

PMID:
24567429
30.

Effects of dental adhesives on micronucleus frequency in peripheral blood lymphocytes in vitro.

Prica D, Tadin A, Marović D, Katunarić M, Prica A, Galić N.

Acta Clin Croat. 2013 Sep;52(3):309-15.

PMID:
24558762
31.

Initial transfusion intensity predicts survival in myelodysplastic syndrome.

Chan LS, Shapiro R, Buckstein R, Lin Y, Callum J, Chodirker L, Lee CD, Prica A, Lam A, Mamedov A, Wells RA.

Leuk Lymphoma. 2014 Oct;55(10):2296-300. doi: 10.3109/10428194.2013.878934. Epub 2014 Feb 24.

PMID:
24397595
32.

Rapidity and quality of response to steroid-based induction therapy, without the addition of novel agents, does not affect post transplant outcomes in multiple myeloma.

Prica A, Trieu Y, Xu W, Reece DE, Trudel S, Kukreti V, Chen C.

Clin Lymphoma Myeloma Leuk. 2013 Feb;13(1):25-31. doi: 10.1016/j.clml.2012.08.008. Epub 2012 Oct 27.

PMID:
23107916
33.

Combined modality therapy versus chemotherapy alone as an induction regimen for primary central nervous system lymphoma: a decision analysis.

Prica A, Chan K, Cheung MC.

Br J Haematol. 2012 Sep;158(5):600-7. doi: 10.1111/j.1365-2141.2012.09208.x. Epub 2012 Jun 26. Review.

PMID:
22734565
34.

Evaluation of an educational program for the caregivers of persons diagnosed with a malignant glioma.

Cashman R, Bernstein LJ, Bilodeau D, Bovett G, Jackson B, Yousefi M, Prica A, Perry J.

Can Oncol Nurs J. 2007 Winter;17(1):6-15. English, French.

PMID:
17847985
35.

Genotoxicity evaluation of five different dentin bonding agents by chromosomal aberration analysis.

Prica D, Galić N, Zeljezić D, Prica A.

J Oral Rehabil. 2006 Jun;33(6):462-71.

PMID:
16671994
36.

[Cerebral hemorrhage and "ecstasy"].

Schlaeppi M, Prica A, de Torrenté A.

Praxis (Bern 1994). 1999 Mar 25;88(13):568-72. German.

PMID:
10235031
37.

[The adaptive characteristics of patients with depressive states].

Mihu S, Prică A, Costin A.

Rev Med Interna Neurol Psihiatr Neurochir Dermatovenerol Neurol Psihiatr Neurochir. 1989 Oct-Dec;34(4):277-82. Romanian. No abstract available.

PMID:
2485929
38.

[General considerations on the somatic equivalents in depressive states].

Prica A.

Rev Med Interna Neurol Psihiatr Neurochir Dermatovenerol Neurol Psihiatr Neurochir. 1988 Oct-Dec;33(4):241-8. Review. Romanian. No abstract available.

PMID:
3076259
39.

A three-year prospective follow-up of psychopathology and social reintegration in paranoid schizophrenia in relation to age at onset.

Prică A, Mihu S, Gherman E, Popovici E, Popescu C, Jipescu I, Neacşu A, Popa S.

Neurol Psychiatr (Bucur). 1988 Jan-Mar;26(1):45-55. No abstract available.

PMID:
3399822
40.

[Catamnestic aspects of neurotic recurrences after the earthquake of 4 March 1977].

Meiu G, Prică A, Radu C.

Rev Med Interna Neurol Psihiatr Neurochir Dermatovenerol Neurol Psihiatr Neurochir. 1981 Oct-Dec;26(4):251-7. Romanian. No abstract available.

PMID:
6213011
41.

[Mental disorders in a heavy industry enterprise].

Prică A, Mihu S, Popovici I, Meiu G, Roman I, Nica S, Aloman A.

Rev Med Interna Neurol Psihiatr Neurochir Dermatovenerol Neurol Psihiatr Neurochir. 1981 Jul-Sep;26(3):215-23. Romanian. No abstract available.

PMID:
6461051
42.

[Clinico-catamnestic aspects of affective psychoses of the pre-senescent period].

Prica A.

Rev Med Interna Neurol Psihiatr Neurochir Dermatovenerol Neurol Psihiatr Neurochir. 1980 Jan-Mar;24(1):49-59. Romanian. No abstract available.

PMID:
6446130
43.

[Aspects of mental disease in the personnel of an industrial unit in Bucharest and analysis of the high risk factors for neuroses].

Predescu V, Prica A, Meiu G, Popovici E, Dumitrescu V, Mihu S, Nica S, Roman I, Aloman A.

Rev Med Interna Neurol Psihiatr Neurochir Dermatovenerol Neurol Psihiatr Neurochir. 1979 Apr-Jun;24(2):117-26. Romanian. No abstract available.

PMID:
504845
44.

Observations on neurasthenia and neurasthenia-like syndromes in a group of women working in textile industry.

Predescu V, Nica ST, Meiu G, Prica A, Cucu I, Damian N, Popovici I, Roman I, Grigoroiu M, Curelaru S.

Neurol Psychiatr (Bucur). 1976 Oct-Dec;14(4):245-52. No abstract available.

PMID:
1024262
45.

Neocortical reactivity to peripheral stimuli in neurotics.

Crighel E, Predescu V, Matei M, Nica S, Prica A.

Neuropsychobiology. 1976;2(4):258-68.

PMID:
1012458
46.

[Contribution of the sentence-completing method to the study of psychogenia].

Dosios A, Constantinescu GN, Alexandru S, Teodorescu M, Prică A.

Neurol Psihiatr Neurochir. 1969 Mar-Apr;14(2):175-8. Romanian. No abstract available.

PMID:
5804688
47.

[Difficulties of attaining the level of aspiration as a psychogenic factor].

Dosios A, Alexandru S, Neicu V, Prică A, Teodorescu M.

Neurol Psihiatr Neurochir. 1968 May-Jun;13(3):263-7. Romanian. No abstract available.

PMID:
5696341
48.

[Contribution of the biographical method and of the questionnaire to the study of depressive-reactive states].

Dosios A, Alexandru S, Neicu V, Prică A.

Neurol Psihiatr Neurochir. 1967 May-Jun;12(3):273-81. Romanian. No abstract available.

PMID:
5594663

Supplemental Content

Support Center